Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - A reason for glycemic control

European Journal of Medical Research

Volumn 13, Issue 5, 2008, Pages 209-214

  Blass, S C ^a   Ellinger, S ^a   Vogel, M ^a   Ingiliz, P ^a   Spengler, U ^a   Stehle, P ^a   von Ruecker, A ^a   Rockstroh, Juergen K ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Glucose metabolism; HIV; Insulin resistance; Obesity; Protease inhibitors; Waist circumference

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; C PEPTIDE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCOSE; INSULIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABDOMINAL FAT; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DISORDERS OF CARBOHYDRATE METABOLISM; FAMILIAL DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LONG TERM CARE; MALE; OBESITY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKINFOLD THICKNESS; TREATMENT DURATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ABDOMINAL FAT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GLUCOSE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT;

EID: 45849151297     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998,338: 853-860.
2. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005,40:1492-1499.
3. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21:743-752.
4. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000,31:1467-1475
5. Gelato MC. Insulin and carbohydrate dysregulation. Clin Infect Dis 2003,36:S91-95.
6. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 1997,20 Suppl 1:S1-70.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985,28:412-419.
8. Manchanda T, Schiedel D, Fischer D, Dekaban GA, Rieder MJ. Adverse drug reactions to protease inhibitors. Can J Clin Pharmacol 2002,9:137-146.
9. Lien LF, Feinglos MN. Protease inhibitor-induced diabetic complications: incidence, management and prevention. Drug Saf 2005,28:209-226.
10. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. Aids 1999,13:F63-70.
11. Walli R, Goebel FD, Demant T. Impaired glucose tolerance and protease inhibitors. Ann Intern Med 1998,129: 837-838.
12. Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007,44:506-517.
13. Despres JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007,6:51-59.
14. Woerle HJ, Mariuz PR, Meyer C, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003,52:918-925.
15. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003,37 Suppl 2:S85-90.
16. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999,353:2093-2099.
17. Combe H, Vol S, Thevenot A, et al. Comparison of men with impaired fasting glycaemia to controls and to diabetic subjects with fasting glycaemia from 7.0 to 7.7 mmol/l: clinical, nutritional and biological status. Diabetes Metab 2004,30:167-174.
18. Abbasi F, Brown BW, Jr., Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002,40:937-943.
19. Bogardus C, Lillioja S, Mott D, Reaven GR, Kashiwagi A, Foley JE. Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in man. Int J Obes 1985,9 Suppl 1:149.
20. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002,162:2074-2079.
21. Lopatynski J, Mardarowicz G, Szczesniak G. A comparative evaluation of waist circumference, waist-to-hip ratio, waist-to-height ratio and body mass index as indicators of impaired glucose tolerance and as risk factors for type-2 diabetes mellitus. Ann Univ Mariae Curie Sklodowska [Med] 2003,58:413-419.